Circulation Journal
Online ISSN : 1347-4820
Print ISSN : 1346-9843
ISSN-L : 1346-9843
Late Breaking Clinical Trials (JCS 2025)
Impact of Guideline-Directed Medical Therapy on 2-Year Mortality in Japanese Patients Undergoing Endovascular Therapy for Femoropopliteal Lesions ― Results of the Multicenter GEMINI-FP Study ―
Tatsuro Takei Takahiro TokudaNaoki YoshiokaKenji OgataAkiko TanakaShunsuke KojimaKohei YamaguchiTakashi YanagiuchiTatsuya Nakamaon behalf of the LEADers PAD Investigators
Author information
JOURNAL OPEN ACCESS FULL-TEXT HTML

2025 Volume 89 Issue 5 Pages 638-646

Details
Abstract

Background: The effect of guideline-directed medical therapy (GDMT) on mid-term mortality in Asian patients, including Japanese patients, who have undergone endovascular therapy (EVT) for lower extremity artery disease remains still unclear. This study evaluated the effects of GDMT, defined as the combined prescription of antiplatelet agents, statins, and angiotensin-converting enzyme inhibitors or angiotensin receptor blockers, on 2-year mortality in Japanese patients undergoing EVT for femoropopliteal (FP) lesions.

Methods and Results: In this multicenter retrospective study, 1,756 registered patients were divided into 2 groups: those who received all 3 medications that comprised GDMT (full GDMT group) and those who received ≤2 medications (non-GDMT group). After propensity score matching, the baseline characteristics did not differ significantly between the 413 pairs of participants in the full GDMT and non-GDMT groups. All-cause mortality within 2 years was significantly lower in the full GDMT than non-GDMT group (14.3% vs. 20.8%; log-rank P=0.030). Mortalities from cardiovascular and cardiocerebrovascular diseases within 2 years were also significantly lower in the GDMT group (4.2% vs. 9.5% [log-rank P=0.021] and 4.2% vs. 10.5% [log-rank P=0.007], respectively).

Conclusions: In Japanese patients undergoing EVT for FP lesions, GDMT may improve all-cause, cardiovascular, and cardiocerebrovascular mortality within 2 years.

Content from these authors
© 2025, THE JAPANESE CIRCULATION SOCIETY

This article is licensed under a Creative Commons [Attribution-NonCommercial-NoDerivatives 4.0 International] license.
https://creativecommons.org/licenses/by-nc-nd/4.0/
Previous article Next article
feedback
Top